Translation of clinical problems in osteoarthritis into pathophysiological research goals by van der Kraan, Peter M et al.
VIEWPOINT
Translation of clinical problems in
osteoarthritis into pathophysiological
research goals
Peter M van der Kraan,1 Francis Berenbaum,2 Francisco J Blanco,3
de Bari Cosimo,4 Floris Lafeber,5 Ellen Hauge,6 Adele Higginbottom,7
Andreea Ioan-Facsinay,8 John Loughlin,9 Ingrid Meulenbelt,10 Eeva Moilanen,11
Irene Pitsillidou,12 Aspasia Tsezou,13 Joyce van Meurs,14 Tonia Vincent,15
Ruth Wittoek,16 Rik Lories,17 On behalf of the EULAR Study group in OA (http://
www.eular.org/investigative_rheumatology_study_groups.cfm)
To cite: van der Kraan PM,
Berenbaum F, Blanco FJ,
et al. Translation of clinical
problems in osteoarthritis
into pathophysiological
research goals. RMD Open
2016;2:e000224.
doi:10.1136/rmdopen-2015-
000224
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
rmdopen-2015-000224).
Received 8 December 2015
Revised 29 February 2016
Accepted 7 March 2016
For numbered affiliations see
end of article.
Correspondence to
Dr Peter M van der Kraan;
peter.vanderkraan@
radboudumc.nl
ABSTRACT
Osteoarthritis (OA) accounts for more disability among
the elderly than any other disease and is associated
with an increased mortality rate. The prevalence in
Europe will rise in the future since this continent has a
strongly ageing population and an obesity epidemic;
obesity and age both being major risk factors for OA.
No adequate therapeutic options, besides joint
replacement, are available, although they are greatly
needed and should be acquired by adequate research
investments. However, the perspective on OA from a
researcher’s point of view is not always aligned with
the perspective of a patient with OA. Researchers base
their views on OA mainly on abnormalities in structure
and function while patients consider OA as a collection
of symptoms. In this viewpoint paper, we discuss the
possibility of translating the most important clinical
problems into pathophysiological research goals to
facilitate the translation from bench to bedside and vice
versa. This viewpoint is the outcome of a dialogue
within the ‘European League Against Rheumatism
study group on OA’ and People with Arthritis/
Rheumatism across Europe (PARE) representatives.
OSTEOARTHRITIS (OA) IS A HUGE AND EVER
INCREASING PROBLEM
OA is the most prevalent joint disease and
accounts for more disability among the
elderly than any other disease. It is estimated
that OA affects about 40 million people in
Europe.1 2 OA can affect each and every
joint but is most common in the knee, hip,
spine and hand. Clinically, it is characterised
by joint pain, limitation of movement, ten-
derness, stiffness, crepitus and various
degrees of inﬂammation. OA is considered a
disease of the whole joint organ; structural
changes include cartilage ﬁbrillation,
ﬁssures, full thickness loss of articular cartil-
age, osteophyte formation, changes in the
subchondral bone plate, synovitis and ﬁbrosis
in synovium or capsule.
To provide exact numbers on the inci-
dence and prevalence of disease is a difﬁcult
task. A major cause of this is the fact that
radiographic changes are not always asso-
ciated with joint pain and vice versa.
Moreover, OA is generally a slow progressive
disease. Epidemiological studies are difﬁcult
to compare due to differences in study popu-
lation and disease criteria. OA is relatively
infrequent in people under the age of
40 years but deﬁnitely increases with age.
Under the age of 45 years, women are less
affected than males, but this gender differ-
ence reverses above 45 years. Europe has an
increasingly ageing population as well as an
obesity epidemic; old age and obesity are
both major risk factors for OA. Since cur-
rently no therapeutic options other than
pain control and joint replacement are avail-
able, the burden of OA will continue to rise
in the coming decades.
ABSENCE OF EFFECTIVE PHARMACOLOGICAL
TREATMENT
Analgaesics, ranging from paracetamol and
opiates to non-steroidal anti-inﬂammatory
drugs (NSAIDs), and intra-articular hyaluro-
nan, are prescribed for treating pain but
their effect is often small (mean effect-size
from 0.15 to 0.30) and in many patients not
sufﬁcient. Osteoarthritic joints that show
signs of inﬂammation are often treated with
intra-articular corticosteroid. Another very
important opportunity in OA management is
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change in lifestyle, mainly by increasing physical activity
and improving physical condition, for example, by
weight loss. Trials are ongoing with newer treatments for
joint pain that are promising but sometimes with limita-
tions due to unexpected drawbacks, for instance, unex-
pected rapid disease progression in some patients
treated with an anti nerve growth factor strategy.3
Treatment of structural disease progression in OA
joints is still a big challenge. Nutraceuticals, symptomatic
slow acting drugs for OA (SYSADOAs) and viscosupple-
mentation are prescribed with this aim in mind,
although there is little evidence to fully support this
claim. Studies with strontium ranelate show effects on
joint space width, but the clinical relevance of the
reported small difference and the potential cardiovascu-
lar side effects have justiﬁed halting its further develop-
ment for patients with OA.4 Ultimately, joint
replacement is the option for patients with severe symp-
toms and end-stage OA. Joint replacement is a rapidly
increasing procedure and over 90% of joints are
replaced due to OA. However, this is a costly procedure
and is, especially in relatively young people, not a per-
manent solution. Moreover, around 20% of the patients
continue to experience some form of joint pain even
after the procedure has been successfully performed.
Thus, the unmet needs in patients with OA are high
and the development of OA treatments that can both
prevent or treat structural break down and improve
symptoms is increasingly needed. Personalised treat-
ment, with a patient-speciﬁc strategy, requires biomar-
kers that stratify patients based on OA subtype and
speciﬁc pathophysiological processes involved, also
taking into account that these processes evolve in a per-
sonal manner during the progression of disease.
PATIENT AND RESEARCHER PERSPECTIVE ON OA
As is adequately exempliﬁed by the paper of Kraus et al,
the perspective on OA from a researcher’s point of view
is quite different from the perspective of a patient with
OA.5 While the main focus of the researcher is on
genes, proteins and cells, signalling, and metabolic path-
ways and structural aspects, the focus of the patient is on
pain, functional limitations, aesthetic damage due to
bony proliferations and loss of daily and social activities.
A researcher views OA as a ‘disease’ based on its abnor-
malities in structure and function originating from bio-
logical or (bio)chemical evidence while a patient
considers OA as an illness, ‘the human response to
disease’.6
Starting from basic pathophysiological research ques-
tions, researchers have taken major steps in understand-
ing OA. We have come from the opinion on OA as a
simple wear and tear process of articular cartilage to a
concept of OA as an organ disease in complex inter-
action with the human body as a whole. Our under-
standing is increasing enormously and only some
general insights can be mentioned here. Genetic studies
have shown that speciﬁc gene variants (Smad3, Dio2
and GDF5, etc) are associated with OA prevalence and
or severity.7 8 The role of ageing and cell senescence has
been implicated in OA.9 Furthermore, it has been
shown that changes in chondrocyte behaviour, such as
increased production of proteolytic enzymes, and even
most likely changes in chondrocyte differentiation, play
a crucial role in degradation of the articular cartilage
matrix.10 11 These changes in chondrocyte behaviour
are governed by changes in activated signalling pathways
and changed responses of aged and senescent chondro-
cytes to these stimuli.12 13 Changes in the subchondral
bone can predict subsequent symptoms or structural
progression, and, recently, it has been shown that not
only local joint inﬂammation but also low-grade systemic
inﬂammation could contribute to the OA disease
process.14–16
To gain a further and more robust understanding of
processes that occur in OA, it is important to take into
account interactions between gene expression, epigen-
etic regulation and environment in clinically well-
deﬁned patients.
RECOGNITION OF DIFFERENT OA PHENOTYPES
OA has been historically classiﬁed based on joint loca-
tion but not on the underlying pathophysiological
process.17 It becomes more and more clear that OA,
even in a speciﬁc joint, is better classiﬁed according to
speciﬁc features that are presumably a result of speciﬁc
underlying disease processes.18 End-stage OA in a par-
ticular joint in different patients can be viewed as the
ﬁnal common outcome of a variety of pathophysiological
processes that differ, or have differed, between these
patients. Classiﬁcation, not based on location but on the
underlying disease process, will be a valuable instrument
not only to further elucidate OA pathophysiology and
also to optimise clinical trials, in particular patient
selection.
Not only might better classiﬁcation of patients by OA
phenotype be a major advance, but improved methods
for early detection of OA are of crucial importance as
well. As early OA has an extended subclinical disease
phase early changes in an OA-affected joint remain
under the radar. As a consequence, intervention is
invariably delayed until severe, and maybe even irrevers-
ible, structural damage has occurred. To improve
disease-modifying interventions, methods and strategies
have to be developed that can detect early, meaningful
and predictive OA-associated changes in the joint and
that can track the result of an eventual intervention.
THE OSTEOARTHRITIS RESEARCH SOCIETY
INTERNATIONAL DEFINITION OF OA
OA is a heterogeneous disease and in this viewpoint and
preceding discussions within the European League
Against Rheumatism (EULAR) study group, we use the
draft deﬁnition of the Osteoarthritis Research Society
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International5 as a working deﬁnition. The authors of this
deﬁnition and the OA study group are fully aware that this
deﬁnition will be modiﬁed according to the further eluci-
dation of OA process(es) and disease phenotypes.
Osteoarthritis is a disorder involving movable joints charac-
terised by cell stress and extracellular matrix degradation
initiated by micro- and macro-injury that activates maladap-
tive repair responses including pro-inﬂammatory pathways
of innate immunity. The disease manifests ﬁrst as a molecu-
lar derangement (abnormal joint tissue metabolism) fol-
lowed by anatomic, and/or physiologic derangements
(characterised by cartilage degradation, bone remodelling,
osteophyte formation, joint inﬂammation and loss of
normal joint function) that can culminate in illness.5
TRANSLATION OF CLINICAL PROBLEMS INTO
PATHOPHYSIOLOGICAL RESEARCH GOALS
A recent EULAR initiative identiﬁed four research prior-
ity areas: epidemiology, imaging and biomarkers, patho-
genesis and therapy,2 which served as the basis for the
ﬁrst call for projects issued by Foundation for research
in rheumatology. In this viewpoint paper, classiﬁcation
of relevant pathophysiological research goals is based on
these priority areas (box 1). The research goals that
were identiﬁed within the study group are not priori-
tised, as in our opinion the research goals have to be
reached in parallel. For example, identiﬁcation and val-
idation of targets for therapy are not achievable without
better insight into the OA pathogenesis and improve-
ment of early detection and disease stratiﬁcation.
Moreover, early detection and disease stratiﬁcation
cannot be accomplished without trustworthy imaging
and functional biomarkers.
EPIDEMIOLOGY
Epidemiology is, in a strict sense, not the major method-
ology of pathophysiological research. However, due to
the integration of epidemiology and genetics (genetic
epidemiology) and the recognition of different OA phe-
notypes, research in this area is of high value in bringing
together clinical problems, and pathophysiological
research goals and understanding. Identiﬁcation of
genetic variants in patients with OA, both genomic and
mitochondrial, will identify phenotype-speciﬁc patho-
genic pathways that will be fundament for phenotype-
speciﬁc OA therapies. Moreover, elucidation of the role
of epigenetic changes in speciﬁc OA phenotypes has the
potential to provide a roadmap to targeted and patient
group-speciﬁc therapy.
IMAGING AND BIOMARKERS
Identiﬁcation and validation of imaging technologies
and biomarkers is of utmost importance for early disease
detection, for classiﬁcation of OA phenotypes, disease
activity and prognosis and for evaluation of therapy
response. Imaging and biomarkers should both form a
reliable reﬂection of underlying disease processes.
Ideally, a biomarker itself should be an integral part of
the actual disease process in OA and a sign of a speciﬁc
OA phenotype. Identiﬁcation of OA phenotypes and the
response to stratiﬁed interventions will most likely
depend on the combination of joint imaging and bio-
marker quantiﬁcation.
PATHOGENESIS
The pathogenesis of OA is far from understood and will
be different in the various OA phenotypes. It has
become more and more clear that the whole joint is
affected in OA and that the different tissues of the joint
communicate and inﬂuence each other’s reactions. To
really comprehend the OA disease process, the commu-
nication between the various joint tissues should be
understood in a phenotype-speciﬁc context and be
studied in the very early stages of OA development.
In many patient groups, a causal relationship between
mechanical changes in the joint and OA is probable.
Box 1 Major pathophysiological research goals
Epidemiology (genetic epidemiology)
▸ To identify and elucidate the role of genetic variants in
Osteoarthritis (OA) phenotypes;
▸ To identify and elucidate the role of epigenetics in OA
phenotypes;
▸ To identify and elucidate the role of mitochondrial genetic var-
iants in OA phenotypes.
Imaging and biomarkers
▸ Identify markers for early OA;
▸ Identify markers for OA phenotypes;
▸ Identify markers for disease activity;
▸ Identify markers for disease progression;
▸ Identify predictive markers of therapeutic response;
▸ Identify markers to evaluate the therapeutic response.
Pathogenesis
▸ To understand tissue communication in OA (between cartilage,
subchondral bone, synovium, vessels, adipose tissue);
▸ To understand non-cartilage pathology in OA;
▸ To understand the role of chondrocyte differentiation in OA;
▸ To understand the role of joint trauma and repair in OA;
▸ To understand the mechanism of mechanical joint injury and
the translation to inflammation and repair;
▸ To understand the relationship between synovitis and radio-
graphic progression;
▸ To understand the earliest stages of OA;
▸ To understand the difference between OA phenotypes;
▸ To understand the origins of pain;
▸ To understand the relationship between pain and structure;
▸ To understand the relationship between synovitis and pain;
▸ To understand the relationship between ageing and OA;
▸ To understand the relationship between gender and OA;
▸ To understand the role of systemic factors in OA;
▸ To define the mechanisms by which comorbidities influence
the OA process (fat and glucose metabolism).
Therapy
▸ To identify and validate targets for therapy (symptoms and
structure).
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However, the exact role of mechanical (over) load in
normal joint physiology and OA is not yet known.
Moreover, the role of intrinsic joint repair or failing
intrinsic joint repair in OA is still obscure. The relation-
ship between structural joint changes and symptoms,
among others, pain, is still an enigma. It is not clear
which tissues are the major source of joint pain, perhaps
bone or synovium or whether there is a role for pro-
ducts released by damaged cartilage in joint pain.
The relationship between unavoidable factors, such as
ageing and gender, and OA phenotype-speciﬁc patho-
physiology has still to be elucidated. Furthermore, how
systemic factors and comorbidities, such as obesity and
diabetes, affect the development and progression of OA,
needs further insight.
THERAPY
The major goal of pathophysiological research in OA is
the identiﬁcation and validation of targets for therapy.
These targets can either be structural targets or symp-
tomatic targets, mainly pain. Ideally, these targets should
be combined as a single agent, albeit without ignoring
the fact that different OA phenotypes may require differ-
ent targeted therapies.
This viewpoint article attempts to bridge the gap
between major clinical problems of OA with patho-
physiological research goals of the OA research commu-
nity, to facilitate the translation from bed to bench and
vice versa. It is anticipated that this article can be a
guide for OA researchers, international organisations
and funding agencies to facilitate their discussions on
directions of research and funding.
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